Percheron Therapeutics Appoints Cathryn Clary As Chief Medical Advisor

Percheron Therapeutics Ltd (ASX: PER) shares were trading ~12% higher intra-day after appointing Cathryn Clary, MD, MBA, as Chief Medical Advisor.

Dr Clary is a highly experienced drug development physician, based in New Jersey.

Proven track record

After completing her medical training, Dr Clary spent thirteen years working with Pfizer, Inc (NYSE: PFE) in New York, NY, where she rose to the position of Senior Vice President, US Medical.

She went on to hold senior roles with Ipsen Biopharmaceuticals, Inc, and with Novartis AG (NYSE: NVS).

More recently, she has served as a consultant to emerging biotechnology companies, including a two-year engagement as Consulting Chief Medical Officer at Solid Biosciences (NASDAQ: SLDB), where she oversaw that company’s gene therapy program in Duchenne muscular dystrophy.

Dr Clary holds a Bachelor of Arts degree (cum laude) from Bryn Mawr College, a Medical Doctorate from the University of Missouri-Columbia, and a Master of Business Administration from the University of Delaware.

“An industry veteran”

Percheron CEO Dr James Garner said: “We are thrilled to have an industry veteran like Cathryn join the Percheron team.

“With recruitment to our phase IIb trial now complete, the team is turning its attention to next steps, including potential engagement with regulatory agencies such as FDA.

“Cathryn’s wealth of experience, including her impressive track record in Duchenne muscular dystrophy, will be an enormous asset for the company as we prepare for the next chapter in the development of ATL1102.”

Read: Percheron Therapeutics Completes Recruitment For Phase IIb Study Of ATL1102

“In addition, Cathryn’s extensive networks among clinicians and patient advocacy in the United States will be very helpful as we work to establish ATL1102 as one of the most exciting late-clinical-stage prospects in this challenging disease area,” said Garner.

Transformative period for Percheron

Garner added that Dr Clary will initially join the team in a part-time consulting role, with the opportunity to expand her position as momentum grows in the ATL1102 program.

Watch: Percheron Therapeutics CEO Dr James Garner On JustStocks Video As ATL1102 Study Completes Recruitment

Dr Clary said: “Having previously worked first-hand in the Duchenne field, I am acutely aware of the need for new therapies in this disease.

“I am excited by the potential ATL1102 has shown to date, and I look forward to working with the team to help ensure its success.

“The next six to twelve months will no doubt be a transformative period for Percheron.”

 

Disclaimer

JustStocks provides data and commentary that constitutes general information only. This does not constitute personal, financial or professional advice or assistance. The data and information compiled do not consider your investment objectives or your financial circumstances. JustStocks cannot guarantee this website’s accuracy, completeness, or timeliness. JustStocks accepts no responsibility regarding any inaccuracy, omission, or change in information or articles or the data provided. The information published on this site/page should not be relied upon as a substitute for personal financial or professional advice. The information provided may not be appropriate for your circumstances or needs. JustStocks recommends that you seek professional advice from a qualified advisor before you make any decisions.

Articles of Interest